Alpelisib
Overview
Alpelisib is an oral medication used for the treatment of certain types of breast cancer. It works by inhibiting a specific enzyme called PI3K, which is involved in the growth and survival of cancer cells.
API suppliers (1)
Suppliers of Alpelisib evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
- SCINOPHARM TAIWAN LTDTaiwan1 active DMF
Patent & exclusivity (US)
Per the FDA Orange Book (7 approved US products), the latest listed US patent on Alpelisib expires 17 Feb 2037 and exclusivity 5 Apr 2029. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Alpelisib? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.